Foresight Diagnostics launches PRECISE-HL trial to explore ctDNA-based therapy de-escalation in classical Hodgkin lymphoma (cHL)

March 10, 2025
The trial’s goal is to assess reducing chemotherapy exposure for cHL patients who demonstrate an early response to treatment.

Foresight Diagnostics announced the launch of the PRECISE-HL clinical trial with the University of Washington School of Medicine and the Fred Hutch Cancer Center in Seattle.

The study will use Foresight CLARITY laboratory developed test (LDT), a circulating tumor DNA (ctDNA)-based MRD LDT, to investigate personalizing treatment for patients with advanced-stage classical Hodgkin lymphoma (cHL). The goal of the PRECISE-HL trial is to assess reducing chemotherapy exposure for patients who demonstrate early response to treatment.

The PRECISE-HL trial will enroll patients with newly diagnosed advanced-stage cHL, who will receive two cycles of nivolumab + AVD therapy (doxorubicin, vinblastine, and dacarbazine). After an interim assessment using Foresight CLARITY LDT, patients with undetectable ctDNA will transition to nivolumab monotherapy for two cycles after completing only four cycles of nivolumab + AVD, while patients with detectable ctDNA will continue with the full six cycles of nivolumab + AVD. End of therapy ctDNA-MRD analysis will also be an exploratory endpoint for the trial.

Foresight Diagnostics release

ID 55989370 © Kippy Spilker | Dreamstime.com
dreamstime_xxl_55989370
ID 85189765 © Monkey Business Images | Dreamstime.com
dreamstime_xxl_85189765
By David A Litman on Adobe Stock
adobestock_281980629
ID 341957989 © Maryna Auramchuk | Dreamstime.com
dreamstime_xxl_341957989
ID 186155212 © Noipornpan | Dreamstime.com
dreamstime_xxl_186155212